Clearance of von Willebrand factor

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH07-10-0629
Issue:2008: 99/2 (Feb) pp. 249-455
Pages:271-278

Clearance of von Willebrand factor

Cécile V. Denis1, Olivier D. Christophe1, Beatrijs D. Oortwijn2, Peter J. Lenting2,3

1INSERM U770, Le Kremlin-Bicêtre, France; Univ. Paris-Sud, Le Kremlin-Bicêtre, France; 2Laboratory for Thrombosis and Haemostasis, Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Utrecht, the Netherlands; 3Crucell Holland B.V., Department of Protein Discovery, Leiden, the Netherlands

Summary

The life cycle of von Willebrand factor (VWF) comprises a number of distinct steps,ranging from the controlled expression of theVWF gene in endothelial cells and megakaryocytes to the removal of VWF from the circulation. The various aspects of VWF clearance have been the objects of intense research in the last few years, stimulated by observations thatVWF clearance is a relatively common component of the pathogenesis of type 1 von Willebrand disease (VWD). Moreover, improving the survival of VWF is now considered as a viable therapeutic strategy to prolong the half-life of factor VIII in order to optimise treatment of haemophilia A.The present review aims to provide an overview of recent findings with regard to the molecular basis of VWF clearance. A number of parameters have been identified that influence VWF clearance, including its glycosylation profile and a number of VWF missense mutations. In addition, in-vivo studies have been used to identify cells that contribute to the catabolism of VWF, providing a starting point for the identification of receptors that mediate the cellular uptake ofVWF.Finally, we discuss recent data describing chemically modification of VWF as an approach to prolong the half-life of the VWF/FVIII complex.

Keywords

Animal models, vonWillebrand factor, factorVIII, vonWillebrand disease

DOI

http://dx.doi.org/10.1160/TH07-10-0629

You may also be interested in...

1.

Sanjiv Baxi1, David L. Crandall3, Thomas R. Meier*,1,2, Shirley Wrobleski1, Angela Hawley1, Diana Farris1, Hassan Elokdah4†, Robert Sigler5, Robert G. Schaub**, 3, Thomas Wakefield1, Daniel Myers1, 2

Thrombosis and Haemostasis 2008 99 4: 749-758

http://dx.doi.org/10.1160/TH07-11-0669

2.

Wolfgang Bergmeier1, Anil K. Chauhan2,3, Denisa D. Wagner2,3

Thrombosis and Haemostasis 2008 99 2: 264-270

http://dx.doi.org/10.1160/TH07-10-0638

3.

Valerie Christiaens, Ilse Scroyen, H. Roger Lijnen

Thrombosis and Haemostasis 2008 99 2: 290-294

http://dx.doi.org/10.1160/TH07-10-0589



Articles

You've 185 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...